Best Practices LLC Report Delivers Key Metrics Behind Building and Maintaining an Effective Medical Science Liaison Group

CHAPEL HILL, N.C., July 2 /PRNewswire/ -- Pharmaceutical and biotechnology organizations are increasingly relying on Medical Science Liaisons to share their products' science story with Key Opinion Leaders. Not only have organizations found these medical specialists are more likely than traditional sales representatives to gain access to KOLs and physicians, but also the science background of MSLs enables them to have these critical conversations within the necessary tight timeframes.  

As companies compete for the attention of physicians, key opinion leaders and thought leaders, they increasingly use MSLs to build and strengthen KOL relationships. Best Practices, LLC recently published a report that highlights the optimal size, mix and service frequencies of these elite medical specialists. The research project included observations and insights from 29 leaders with 24 companies including, Abbott, AstraZeneca, Bristol-Myers Squibb, Genentech, Novo Nordisk, Lilly, Novartis and Schering-Plough.

Contrary to industry belief, 89 percent of companies surveyed do not reduce the number of their field-based medical specialists after a product has been launched. The strategic underpinning of that metric is that forging thought leader relationships takes time and is an essential tool for understanding and competing in the marketplace. Best Practices LLC's report, Medical Science Liaisons: Gaining Access and Forging Relationships with Key Opinion Leaders, will provide executives with key metrics such as this to help them create and maintain an effective MSL group.

The key topics covered in this report include:

  • Pre-Launch Service Activities
  • Post-Launch Service Activities
  • Drivers of Group Size and Focus
  • Structuring and Aligning Field-Based Liaisons with Sales Organizations
  • Optimal Call Frequencies and Service Levels with Thought Leaders
  • Managing, Shifting and Forecasting Resources

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1009.htm. For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/

ABOUT BEST PRACTICES, LLC

Best Practices, LLC conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 18 years; our clients include 48 out of the top 50 pharmaceutical companies.

SOURCE Best Practices, LLC

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.